|
Name |
Methyl 14-methylhexadecanoate
|
| Molecular Formula | C18H36O2 | |
| IUPAC Name* |
methyl 14-methylhexadecanoate
|
|
| SMILES |
CCC(C)CCCCCCCCCCCCC(=O)OC
|
|
| InChI |
InChI=1S/C18H36O2/c1-4-17(2)15-13-11-9-7-5-6-8-10-12-14-16-18(19)20-3/h17H,4-16H2,1-3H3
|
|
| InChIKey |
AOAFVSVYRSUDBN-UHFFFAOYSA-N
|
|
| Synonyms |
Methyl 14-methylhexadecanoate; 2490-49-5; Hexadecanoic acid, 14-methyl-, methyl ester; Methyl 14-methyl-8-hexadecenoate; WE(1:0/16:1(8)(14Me)); METHYL14-METHYLHEXADECANOATE; Hexadecanoicacid, 14-methyl-, methyl ester; SCHEMBL891693; methyl 14-methylhexa-decanoate; DTXSID001016325; LMFA07010527; 14-Methylhexadecanoic acid methyl ester; Hexadecanoicacid,14-methyl-,methyl ester
|
|
| CAS | 2490-49-5 | |
| PubChem CID | 520159 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 284.5 | ALogp: | 7.7 |
| HBD: | 0 | HBA: | 2 |
| Rotatable Bonds: | 15 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 26.3 | Aromatic Rings: | 0 |
| Heavy Atoms: | 20 | QED Weighted: | 0.29 |
| Caco-2 Permeability: | -4.716 | MDCK Permeability: | 0.00001420 |
| Pgp-inhibitor: | 0.092 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.969 |
| 30% Bioavailability (F30%): | 0.986 |
| Blood-Brain-Barrier Penetration (BBB): | 0.292 | Plasma Protein Binding (PPB): | 97.26% |
| Volume Distribution (VD): | 1.836 | Fu: | 1.51% |
| CYP1A2-inhibitor: | 0.66 | CYP1A2-substrate: | 0.209 |
| CYP2C19-inhibitor: | 0.46 | CYP2C19-substrate: | 0.142 |
| CYP2C9-inhibitor: | 0.323 | CYP2C9-substrate: | 0.926 |
| CYP2D6-inhibitor: | 0.15 | CYP2D6-substrate: | 0.047 |
| CYP3A4-inhibitor: | 0.434 | CYP3A4-substrate: | 0.094 |
| Clearance (CL): | 5.57 | Half-life (T1/2): | 0.228 |
| hERG Blockers: | 0.132 | Human Hepatotoxicity (H-HT): | 0.035 |
| Drug-inuced Liver Injury (DILI): | 0.279 | AMES Toxicity: | 0.005 |
| Rat Oral Acute Toxicity: | 0.018 | Maximum Recommended Daily Dose: | 0.027 |
| Skin Sensitization: | 0.955 | Carcinogencity: | 0.059 |
| Eye Corrosion: | 0.938 | Eye Irritation: | 0.95 |
| Respiratory Toxicity: | 0.897 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000549 | ![]() |
0.893 | D07ILQ | ![]() |
0.487 | ||
| ENC000548 | ![]() |
0.817 | D0P1RL | ![]() |
0.477 | ||
| ENC001160 | ![]() |
0.806 | D0Z5SM | ![]() |
0.467 | ||
| ENC000848 | ![]() |
0.769 | D05ATI | ![]() |
0.431 | ||
| ENC001519 | ![]() |
0.767 | D0O1PH | ![]() |
0.419 | ||
| ENC000604 | ![]() |
0.763 | D0G2KD | ![]() |
0.405 | ||
| ENC001260 | ![]() |
0.754 | D00FGR | ![]() |
0.394 | ||
| ENC000560 | ![]() |
0.754 | D0T9TJ | ![]() |
0.375 | ||
| ENC000803 | ![]() |
0.733 | D00MLW | ![]() |
0.373 | ||
| ENC000271 | ![]() |
0.719 | D00AOJ | ![]() |
0.367 | ||